Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228481 | 0.89 | HSD17B10 (0.38) | HSD17B10NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL31228310 | 0.86 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL31228414 | 0.83 | KMT2A (0.32) | KMT2ASMN1; SMN2 | |
| SCHEMBL31228409 | 0.82 | — | — | |
| SCHEMBL31228575 | 0.81 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL31153653 | 0.76 | NR1H2 (0.30) | SMN1; SMN2 | |
| SCHEMBL31228189 | 0.74 | MMP3 (0.31) | KMT2A | |
| SCHEMBL31228509 | 0.74 | MMP3 (0.31) | KMT2A | |
| SCHEMBL31228362 | 0.74 | MMP3 (0.31) | KMT2A | |
| SCHEMBL31228607 | 0.70 | ATM (0.31) | RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211663-A9 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024211663-A1 | CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-10 | — | — | WO | disclosed |